|
WO2009091531A2
(en)
*
|
2008-01-16 |
2009-07-23 |
The General Hospital Corporation |
Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
|
|
WO2011140393A1
(en)
|
2010-05-05 |
2011-11-10 |
Prolynx Llc |
Controlled release from macromolecular conjugates
|
|
CN103796684B
(zh)
|
2011-06-06 |
2019-06-25 |
星法马私人有限公司 |
大分子
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
US9649385B2
(en)
|
2011-09-07 |
2017-05-16 |
Prolynx Llc |
Hydrogels with biodegradable crosslinking
|
|
EP2850201A4
(en)
*
|
2012-05-11 |
2016-08-31 |
Alexander Krantz |
Site-specific labeling and targeted administration of proteins for the treatment of cancer
|
|
US20150352246A1
(en)
*
|
2013-01-22 |
2015-12-10 |
Prolynx Llc |
Sealants having controlled degration
|
|
JP6622192B2
(ja)
|
2013-06-19 |
2019-12-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
治療薬を局所的送達するための化学構造
|
|
SG10201803370XA
(en)
*
|
2013-10-22 |
2018-06-28 |
Prolynx Llc |
Conjugates of somatostatin and its analogs
|
|
IL301674A
(en)
*
|
2013-12-19 |
2023-05-01 |
Seagen Inc |
Methylene carbamate binders for use with drug-targeting conjugates
|
|
CN106659796B
(zh)
|
2014-03-14 |
2021-04-30 |
加利福尼亚大学董事会 |
Tco缀合物和治疗剂递送方法
|
|
IL259827B2
(en)
|
2016-01-08 |
2025-07-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low initial NPR-B activity
|
|
EP3400020A1
(en)
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
CN115177720A
(zh)
|
2016-01-08 |
2022-10-14 |
阿森迪斯药物生长障碍股份有限公司 |
具有低npr-c结合的控制释放cnp激动剂
|
|
US11389511B2
(en)
|
2016-01-08 |
2022-07-19 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with reduced side-effects
|
|
SI3400019T1
(sl)
|
2016-01-08 |
2023-01-31 |
Ascendis Pharma Growth Disorders Division A/S |
Predzdravila CNP s povezavo nosilca na obročni ostanek
|
|
MX2018008050A
(es)
|
2016-01-08 |
2018-08-23 |
Ascendis Pharma Growth Disorders As |
Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
|
|
US20200276276A1
(en)
|
2016-03-01 |
2020-09-03 |
Ascendis Pharma Bone Diseases A/S |
PTH Prodrugs
|
|
SG11201807832VA
(en)
*
|
2016-03-16 |
2018-10-30 |
Prolynx Llc |
Extended release conjugates of exenatide analogs
|
|
EP3484523A1
(en)
|
2016-07-13 |
2019-05-22 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
ES2943013T3
(es)
|
2016-09-29 |
2023-06-08 |
Ascendis Pharma Growth Disorders As |
Terapia de combinación con agonistas del CNP de liberación controlada
|
|
HUE063235T2
(hu)
|
2016-09-29 |
2024-01-28 |
Ascendis Pharma Bone Diseases As |
Adagolási rendszer szabályozott leadású PTH vegyülethez
|
|
DK3518961T5
(da)
|
2016-09-29 |
2024-09-02 |
Ascendis Pharma Bone Diseases As |
PTH-forbindelser med lave forhold mellem top og bund
|
|
SMT202500059T1
(it)
|
2016-09-29 |
2025-03-12 |
Ascendis Pharma Bone Diseases As |
Composti pth a rilascio controllato
|
|
JOP20190191A1
(ar)
|
2017-02-22 |
2019-08-08 |
Astrazeneca Ab |
وحدات شجرية علاجية
|
|
CN110891611B
(zh)
|
2017-03-22 |
2024-03-29 |
阿森迪斯制药公司 |
水凝胶交联透明质酸前药组合物和方法
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
EP3684785B1
(en)
|
2017-09-19 |
2024-10-02 |
Technische Universität München |
N-methylated cyclic peptides and their prodrugs
|
|
EP3684417A1
(en)
*
|
2017-09-19 |
2020-07-29 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Lipophilic peptide prodrugs
|
|
AU2019208024A1
(en)
|
2018-01-12 |
2020-08-13 |
Prolynx Llc |
Protocol for minimizing toxicity of combination dosages and imaging agent for verification
|
|
EP3765096A1
(en)
|
2018-03-12 |
2021-01-20 |
Boston Scientific Scimed Inc. |
Scavenging methods, and scavenging system for radiocontrast agents
|
|
CA3093083A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugates
|
|
CN119504973A
(zh)
|
2018-03-28 |
2025-02-25 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2缀合物
|
|
EP4609879A3
(en)
|
2018-05-18 |
2025-12-17 |
Ascendis Pharma Bone Diseases A/S |
Starting dose of pth conjugates
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
JP7588065B2
(ja)
|
2018-07-19 |
2024-11-21 |
スターファーマ ピーティーワイ エルティーディー |
治療用デンドリマー
|
|
JP7701873B2
(ja)
|
2018-09-26 |
2025-07-02 |
アセンディス ファーマ エー／エス |
分解性ヒアルロン酸ヒドロゲル
|
|
AU2019345987A1
(en)
|
2018-09-26 |
2021-03-25 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
|
WO2020064844A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Treatment of infections
|
|
TW202027794A
(zh)
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣３多肽之持續遞送
|
|
BR112021011592A2
(pt)
|
2019-01-04 |
2021-10-26 |
Ascendis Pharma Oncology Division A/S |
Conjugados de agonistas de receptor de reconhecimento de padrão
|
|
WO2020141225A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma A/S |
Minimization of systemic inflammation
|
|
CN113316452A
(zh)
|
2019-01-04 |
2021-08-27 |
阿森迪斯药物肿瘤股份有限公司 |
先天性免疫激动剂的持续局部药物水平
|
|
US20220054477A1
(en)
|
2019-01-04 |
2022-02-24 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
|
SG11202107446QA
(en)
|
2019-02-11 |
2021-08-30 |
Ascendis Pharma Growth Disorders As |
Dry pharmaceutical formulations of cnp conjugates
|
|
BR112021014581A2
(pt)
|
2019-02-11 |
2021-12-14 |
Ascendis Pharma Bone Diseases As |
Formulações farmacêuticas líquidas de conjugados de pth
|
|
KR20210150496A
(ko)
|
2019-04-05 |
2021-12-10 |
프로린크스 엘엘시 |
개선된 컨쥬게이션 링커
|
|
CN114126638A
(zh)
*
|
2019-04-26 |
2022-03-01 |
普罗林科斯有限责任公司 |
缓慢释放的细胞因子偶联物
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
CA3143278A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
CA3143279A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 conjugates
|
|
CN114026080A
(zh)
*
|
2019-06-21 |
2022-02-08 |
阿森迪斯药物股份有限公司 |
含有提供π-电子对的杂芳族氮的化合物的缀合物
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
US20220401561A1
(en)
*
|
2019-09-30 |
2022-12-22 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Protein-macromolecule conjugates and methods of use thereof
|
|
AU2021208398A1
(en)
|
2020-01-13 |
2022-06-09 |
Ascendis Pharma Bone Diseases A/S |
Hypoparathyroidism treatment
|
|
AU2021269007A1
(en)
|
2020-05-04 |
2022-11-24 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
|
WO2021245130A1
(en)
|
2020-06-03 |
2021-12-09 |
Ascendis Pharma Oncology Division A/S |
Il-2 sequences and uses thereof
|
|
US20230340055A1
(en)
|
2020-08-28 |
2023-10-26 |
Ascendis Pharma Oncology Division A/S |
Glycosylated il-2 proteins and uses thereof
|
|
MX2023003540A
(es)
|
2020-09-28 |
2023-04-21 |
Ascendis Pharma Bone Diseases As |
Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.
|
|
IL307192A
(en)
|
2021-04-01 |
2023-11-01 |
Ascendis Pharma As |
Long-term use of growth hormone to treat diseases caused by inflammation
|
|
EP4404951A1
(en)
|
2021-09-22 |
2024-07-31 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
|
WO2023069510A1
(en)
*
|
2021-10-19 |
2023-04-27 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
CA3236278A1
(en)
|
2021-12-13 |
2023-06-22 |
Kennett Sprogoe |
Effective doses of cnp conjugates
|
|
CA3238942A1
(en)
|
2021-12-13 |
2023-06-22 |
Vibeke MILLER BREINHOLT |
Cancer treatments with tlr7/8 agonists
|
|
CN119789847A
(zh)
|
2022-05-23 |
2025-04-08 |
阿森迪斯药物生长障碍股份有限公司 |
Cnp化合物的液体药物制剂
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
CN120752051A
(zh)
|
2022-11-02 |
2025-10-03 |
阿森迪斯药物骨疾病股份有限公司 |
包含两种pth化合物的pth治疗方案
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
IL323019A
(en)
|
2023-03-06 |
2025-10-01 |
Ascendis Pharma As |
Drug compounds with an albumin-binding moiety
|
|
WO2024184354A1
(en)
|
2023-03-06 |
2024-09-12 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
KR20250131829A
(ko)
|
2023-03-06 |
2025-09-03 |
아센디스 파마 에이에스 |
알부민 결합 모이어티를 포함하는 약물 화합물
|
|
KR20250162619A
(ko)
|
2023-03-20 |
2025-11-18 |
아센디스 파마 그로우쓰 디스오더스 에이/에스 |
연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
|
|
CN121175071A
(zh)
|
2023-05-09 |
2025-12-19 |
阿森迪斯药物肿瘤股份有限公司 |
使用il-2缀合物的新型癌症治疗方法
|
|
WO2025051711A1
(en)
|
2023-09-04 |
2025-03-13 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
WO2025208117A1
(en)
*
|
2024-03-29 |
2025-10-02 |
Maha Therapeutics, Inc. |
Cleavable ester compounds and uses thereof
|